Advertisement

Tumor Biology

, Volume 37, Issue 4, pp 5117–5131 | Cite as

Integrin β6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC)

  • Zequn Li
  • Pengfei Lin
  • Chao Gao
  • Cheng Peng
  • Song Liu
  • Huijie Gao
  • Ben Wang
  • Jiayong Wang
  • Jun Niu
  • Weibo Niu
Original Article

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most deadly cancers and is expected to become the second leading cause of cancer death by 2030. Despite extensive efforts to improve surgical treatment, limited progress has been made. Increasing evidence indicates that integrin β6 plays a crucial role in carcinoma invasion and metastasis. However, the expression and role of β6 in PDAC remain largely unknown. In the present study, we investigated the expression of β6 in PDAC and its potential value as a prognostic factor and therapeutic target. β6 upregulation was identified as an independent unfavorable prognostic indicator. Integrin β6 markedly promoted the proliferation and invasion of pancreatic carcinoma cells and induced ETS1 phosphorylation in an ERK-dependent manner, leading to the upregulation of matrix metalloprotease-9, which is essential for β6-mediated invasiveness of pancreatic carcinoma cells. Accordingly, small interfering RNA-mediated silencing of integrin β6 markedly suppressed xenograft tumor growth in vivo. Taken together, our results suggest that integrin β6 plays important roles in the progression of pancreatic carcinoma and contributes to reduced survival times, and may serve as a novel therapeutic target for the treatment of PDAC.

Keywords

Integrin β6 PDAC Prognostic indicator Invasiveness ETS1 

Notes

Acknowledgments

This study is supported by National Natural Science Foundation of China (no. 81272653) and by Natural Science Foundation of Shandong Province (no. ZR2015HM071). The authors thank Biogen Idec for the special antibodies and Professor Hui Wang for the assistance in statistical analysis.

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi: 10.3322/caac.21208.CrossRefPubMedGoogle Scholar
  2. 2.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. doi: 10.1002/ijc.29210.CrossRefPubMedGoogle Scholar
  3. 3.
    Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21. doi: 10.1158/0008-5472.CAN-14-0155.CrossRefPubMedGoogle Scholar
  4. 4.
    Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049–57. doi: 10.1016/S0140-6736(04)15841-8.CrossRefPubMedGoogle Scholar
  5. 5.
    Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7(3):163–72. doi: 10.1038/nrclinonc.2009.236.CrossRefPubMedGoogle Scholar
  6. 6.
    Li HY, Cui ZM, Chen J, Guo XZ, Li YY. Pancreatic cancer: diagnosis and treatments. Tumour Biol. 2015;36(3):1375–84. doi: 10.1007/s13277-015-3223-7.CrossRefPubMedGoogle Scholar
  7. 7.
    Bandyopadhyay A, Raghavan S. Defining the role of integrin alphavbeta6 in cancer. Curr Drug Targets. 2009;10(7):645–52.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis. 2003;20(3):203–13.CrossRefPubMedGoogle Scholar
  9. 9.
    Thomas GJ, Nystrom ML, Marshall JF. Alphavbeta6 integrin in wound healing and cancer of the oral cavity. J Oral Pathol Med. 2006;35(1):1–10. doi: 10.1111/j.1600-0714.2005.00374.x.CrossRefPubMedGoogle Scholar
  10. 10.
    Li HX, Zheng JH, Fan HX, Li HP, Gao ZX, Chen D. Expression of alphavbeta6 integrin and collagen fibre in oral squamous cell carcinoma: association with clinical outcomes and prognostic implications. J Oral Pathol Med. 2013;42(7):547–56. doi: 10.1111/jop.12044.CrossRefPubMedGoogle Scholar
  11. 11.
    Li W, Liu Z, Zhao C, Zhai L. Binding of MMP-9-degraded fibronectin to beta6 integrin promotes invasion via the FAK-Src-related Erk1/2 and PI3K/Akt/Smad-1/5/8 pathways in breast cancer. Oncol Rep. 2015. doi: 10.3892/or.2015.4103.Google Scholar
  12. 12.
    Liu S, Wang J, Niu W, Liu E, Wang J, Peng C, et al. The beta6-integrin-ERK/MAP kinase pathway contributes to chemo resistance in colon cancer. Cancer Lett. 2013;328(2):325–34. doi: 10.1016/j.canlet.2012.10.004.CrossRefPubMedGoogle Scholar
  13. 13.
    Xue B, Wu W, Huang K, Xie T, Xu X, Zhang H, et al. Stromal cell-derived factor-1 (SDF-1) enhances cells invasion by alphavbeta6 integrin-mediated signaling in ovarian cancer. Mol Cell Biochem. 2013;380(1–2):177–84. doi: 10.1007/s11010-013-1671-1.CrossRefPubMedGoogle Scholar
  14. 14.
    Yang GY, Guo S, Dong CY, Wang XQ, Hu BY, Liu YF, et al. Integrin alphavbeta6 sustains and promotes tumor invasive growth in colon cancer progression. World J Gastroenterol. 2015;21(24):7457–67. doi: 10.3748/wjg.v21.i24.7457.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Zhang ZY, Xu KS, Wang JS, Yang GY, Wang W, Wang JY, et al. Integrin alphanvbeta6 acts as a prognostic indicator in gastric carcinoma. Clin Oncol. 2008;20(1):61–6. doi: 10.1016/j.clon.2007.09.008.CrossRefGoogle Scholar
  16. 16.
    Wang B, Wang W, Niu W, Liu E, Liu X, Wang J, et al. SDF-1/CXCR4 axis promotes directional migration of colorectal cancer cells through upregulation of integrin alphavbeta6. Carcinogenesis. 2014;35(2):282–91. doi: 10.1093/carcin/bgt331.CrossRefPubMedGoogle Scholar
  17. 17.
    Gu X, Niu J, Dorahy DJ, Scott R, Agrez MV. Integrin alpha(v)beta6-associated ERK2 mediates MMP-9 secretion in colon cancer cells. Br J Cancer. 2002;87(3):348–51. doi: 10.1038/sj.bjc.6600480.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Gao H, Peng C, Liang B, Shahbaz M, Liu S, Wang B, et al. β6 integrin induces the expression of metalloproteinase-3 and metalloproteinase-9 in colon cancer cells via ERK-ETS1 pathway. Cancer Lett. 2014;354(2):427–37. doi: 10.1016/j.canlet.2014.08.017.CrossRefPubMedGoogle Scholar
  19. 19.
    Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest. 2005;115(2):339–47. doi: 10.1172/JCI23183.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ahmed N, Niu J, Dorahy DJ, Gu X, Andrews S, Meldrum CJ, et al. Direct integrin alphavbeta6-ERK binding: implications for tumour growth. Oncogene. 2002;21(9):1370–80. doi: 10.1038/sj.onc.1205286.CrossRefPubMedGoogle Scholar
  21. 21.
    Niu W, Liu X, Zhang Z, Xu K, Chen R, Liu E, et al. Effects of alphavbeta6 gene silencing by RNA interference in PANC-1 pancreatic carcinoma cells. Anticancer Res. 2010;30(1):135–42.PubMedGoogle Scholar
  22. 22.
    Agrez M, Chen A, Cone RI, Pytela R, Sheppard D. The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain. J Cell Biol. 1994;127(2):547–56.CrossRefPubMedGoogle Scholar
  23. 23.
    Ahmed N, Pansino F, Clyde R, Murthi P, Quinn MA, Rice GE, et al. Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis. 2002;23(2):237–44.CrossRefPubMedGoogle Scholar
  24. 24.
    Marechal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, et al. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer. 2009;100(9):1444–51. doi: 10.1038/sj.bjc.6605020.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Zhang YJ, Dai Q, Sun DF, Xiong H, Tian XQ, Gao FH, et al. mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann Surg Oncol. 2009;16(9):2617–28. doi: 10.1245/s10434-009-0555-9.CrossRefPubMedGoogle Scholar
  26. 26.
    Defilles C, Lissitzky JC, Montero MP, Andre F, Prevot C, Delamarre E, et al. alphavbeta5/beta6 integrin suppression leads to a stimulation of alpha2beta1 dependent cell migration resistant to PI3K/Akt inhibition. Exp Cell Res. 2009;315(11):1840–9. doi: 10.1016/j.yexcr.2009.03.014.CrossRefPubMedGoogle Scholar
  27. 27.
    Lee J, Hun Yun J, Lee J, Choi C, Hoon KJ. Blockade of dual-specificity phosphatase 28 decreases chemo-resistance and migration in human pancreatic cancer cells. Sci Rep. 2015;5:12296. doi: 10.1038/srep12296.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Breuss JM, Gillett N, Lu L, Sheppard D, Pytela R. Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues. J Histochem Cytochem. 1993;41(10):1521–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Arihiro K, Kaneko M, Fujii S, Inai K, Yokosaki Y. Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma. Breast Cancer. 2000;7(1):19–26.CrossRefPubMedGoogle Scholar
  30. 30.
    Sipos B, Hahn D, Carceller A, Piulats J, Hedderich J, Kalthoff H, et al. Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology. 2004;45(3):226–36. doi: 10.1111/j.1365-2559.2004.01919.x.CrossRefPubMedGoogle Scholar
  31. 31.
    Thomas GJ, Lewis MP, Hart IR, Marshall JF, Speight PM. AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer. 2001;92(5):641–50.CrossRefPubMedGoogle Scholar
  32. 32.
    Elayadi AN, Samli KN, Prudkin L, Liu YH, Bian A, Xie XJ, et al. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 2007;67(12):5889–95. doi: 10.1158/0008-5472.CAN-07-0245.CrossRefPubMedGoogle Scholar
  33. 33.
    Liang B, Shahbaz M, Wang Y, Gao H, Fang R, Niu Z, et al. Integrinbeta6-targeted immunoliposomes mediate tumor-specific drug delivery and enhance therapeutic efficacy in colon carcinoma. Clin Cancer Res. 2015;21(5):1183–95. doi: 10.1158/1078-0432.CCR-14-1194.CrossRefPubMedGoogle Scholar
  34. 34.
    Ramos DM, But M, Regezi J, Schmidt BL, Atakilit A, Dang D, et al. Expression of integrin beta 6 enhances invasive behavior in oral squamous cell carcinoma. Matrix Biol. 2002;21(3):297–307.CrossRefPubMedGoogle Scholar
  35. 35.
    Huang X, Wu J, Spong S, Sheppard D. The integrin alphavbeta6 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin. J Cell Sci. 1998;111(Pt 15):2189–95.PubMedGoogle Scholar
  36. 36.
    Xue H, Atakilit A, Zhu W, Li X, Ramos DM, Pytela R. Role of the alpha(v)beta6 integrin in human oral squamous cell carcinoma growth in vivo and in vitro. Biochem Biophys Res Commun. 2001;288(3):610–8. doi: 10.1006/bbrc.2001.5813.CrossRefPubMedGoogle Scholar
  37. 37.
    Wang J, Wu J, Hong J, Chen R, Xu K, Niu W, et al. PKC promotes the migration of colon cancer cells by regulating the internalization and recycling of integrin alphavbeta6. Cancer Lett. 2011;311(1):38–47. doi: 10.1016/j.canlet.2011.06.025.CrossRefPubMedGoogle Scholar
  38. 38.
    Hezel AF, Deshpande V, Zimmerman SM, Contino G, Alagesan B, O’Dell MR, et al. TGF-beta and alphavbeta6 integrin act in a common pathway to suppress pancreatic cancer progression. Cancer Res. 2012;72(18):4840–5. doi: 10.1158/0008-5472.CAN-12-0634.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Leconet W, Larbouret C, Chardes T, Thomas G, Neiveyans M, Busson M, et al. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene. 2014;33(47):5405–14. doi: 10.1038/onc.2013.487.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Zequn Li
    • 1
    • 2
  • Pengfei Lin
    • 1
    • 2
  • Chao Gao
    • 1
  • Cheng Peng
    • 1
  • Song Liu
    • 3
  • Huijie Gao
    • 1
  • Ben Wang
    • 1
  • Jiayong Wang
    • 1
  • Jun Niu
    • 1
  • Weibo Niu
    • 1
  1. 1.Department of General SurgeryQiLu Hospital of Shandong UniversityJinanChina
  2. 2.Key Laboratory of Cardiovascular Remodeling and Function ResearchChinese Ministry of Education and Public HealthJinanChina
  3. 3.Department of Thyroid & Breast SurgeryAffiliated Hospital of Binzhou Medical CollegeBinzhouChina

Personalised recommendations